Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine–Rituximab
Abstract
Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma in Western countries after diffuse large B-cell lymphoma. Most patients with FL present with asymptomatic disease. Survival rates have been rising over time mainly due to advancing therapeutic strategies
A-51-year-old male with a history of well-controlled diabetes mellitus treated with insulin presented to the policlinic of hematology-medical oncology with worsening right inguinal lymphadenopathy for >3 months. He had no complaints of prolonged fever, night sweat, or weight loss. Initial physical examination revealed a healthy male with bulky right inguinal lymphadenopathy. The patient was then referred to a surgeon, and excisional biopsy of the enlarged right inguinal lymph nodes was performed. Therefore, stage II bulky symptomatic low-grade FL was established. We administered chemoimmunotherapy with rituximab and bendamustine every 3 weeks for six cycles. The patient tolerated the treatment well and completed six cycles of chemoimmunotherapy, and the follow-up FDG PET/CT showed complete remission of the disease.
The patient achieved complete remission after series of chemoimmunotherapy with Bendamustine–Rituximab. Future assessment is still required for this patient to ensure the remission status of the lymphoma
Keywords
References
Cho SH, Suh CW, Do YR, et al. Clinical features and survival of patients with follicular lymphoma in Korea. Clin Lymphoma Myeloma Leuk. 2016;16(4):197-202.
Cartron G, Trotman J. Time for an individualized approach to first-line management of follicular lymphoma. Haematologica. 2022;107(1):7-18.
Provencio Pulla M, Alfaro Lizaso J, de la Cruz Merino L, et al. SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma. Clin Transl Oncol. 2015;17(12):1014-9.
Clauwaert M, Galle V, Maerevoet M, et al. Guidelines of the Belgian Hematological Society for newly diagnosed and relapsed follicular lymphoma 2019. Belg J Hematol. 2020;11(2):67-74.
Cerhan JR. Epidemiology of follicular lymphoma. Hematol Oncol Clin North Am. 2020;34(4):631-46.
Muto R, Miyoshi H, Sato K, et al. Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification. Cancer Medicine. 2018;7(11):5843-58.
Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2021;32(3):298-308.
Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicenter, randomized, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-10.
Flinn IW, Van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with Bendamustine plus Rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow up study. J Clin Oncol. 2019;37(12):984-91.
McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma. Brit J Haematol. 2020;191:363-81.
Zoellner A, Herfarth K, Herold M, et al. Clinical practice guideline: Follicular lymphoma—diagnosis, treatment, and follow-up. Dtsch Arztebl Int. 2021;118: 320-5.
Refbacks
- There are currently no refbacks.